Loading clinical trials...
Loading clinical trials...
The Effect Of Medial Olivocochlear Efferents On Speech Discrimination In Noise In Multiple Sclerosis.
The aim of this clinical trial was to determine the effect of multiple sclerosis on speech reception and discrimination in noise and to compare the effects on the medial olivocochlear reflex, which is thought to affect speech intelligibility in noise, with a control group. The main questions it aims to answer are: Does MS disease affect the ability to discriminate speech in noise? Does MS affect contralateral suppression results assessing medial olivocochlear function? Is there a correlation between the ability to discriminate speech in noise and contralateral suppression skills of MS patients? Data from MS patients and healthy participants will be compared. Thirty relapsing remitting MS patients and 30 healthy participants admitted to the clinic will be evaluated.
The second aim was to evaluate the relationship between speech comprehension and discrimination skills in noise and cognitive function and to compare them with the control group. Inclusion Criteria for the Study Group 1. Being diagnosed with MS (Primary Progressive, Secondary Progressive, Relapsing Remittting) - exclusion criteria for the control group 2. Being between 18-50 years old 3. Volunteering 4. Co-operation with the scales and tests to be applied 5. Normal ENT otoscopic (external and middle ear) examination findings 6. Having a normal (type A) tympanogram with a peak value of ± 50 daPa on acoustic impedancemetry examination 7. Pure voice average within normal limits (Clark, 1981). 8. Speech scores within normal limits (Jerger \& Hayes, 1977). 9. No other neurological, psychiatric, metabolic diseases other than MS 10. No history of noise exposure and ototoxic drug use Exclusion Criteria for Volunteers 1\) Not diagnosed with MS (Primary Progressive, Secondary Progressive, Relapsing Remittting) - inclusion criteria for the control group 2) Being younger than 18 years old and older than 50 years old 3) Not wanting to participate in the study or giving up participation 4) Inability to cooperate with the scales and tests to be applied 5) Detection of pathology in ENT otoscopic (external and middle ear) examination findings 6) Obtaining Type B and Type C tympanograms 7) Hearing loss 8) Speech scores are not normal 9) Having any neurological, psychiatric, metabolic disease - MS diagnosis is the inclusion criterion for the study group 10) History of noise exposure and ototoxic drug use The primary endpoint of the study will be to evaluate whether there is a relationship between the MOC reflex and the thresholds for speech reception and discrimination in noise in individuals diagnosed with MS. It will be evaluated whether cognitive function differences in individuals diagnosed with MS show differences in speech in noise and discrimination thresholds.
Age
18 - 50 years
Sex
ALL
Healthy Volunteers
Yes
Ondokuz Mayıs University
Samsun, Turkey (Türkiye)
Start Date
October 9, 2020
Primary Completion Date
March 23, 2023
Completion Date
April 23, 2023
Last Updated
April 24, 2024
60
ACTUAL participants
Hearing test
DIAGNOSTIC_TEST
Speech in noise discrimination test
DIAGNOSTIC_TEST
Montreal Cognitive Assessment Scale
DIAGNOSTIC_TEST
Symbol Number Modalities Test (SDMT)
DIAGNOSTIC_TEST
Lead Sponsor
Asuman Kucukoner
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions